Effect of therapeutic plasma exchange on tissue factor and tissue factor pathway inhibitor in septic shock.
Apheresis
Coagulation
Extracorporeal treatment
Plasmapheresis
Precision medicine
Sepsis
Tissue factor
Tissue factor pathway inhibitor
Journal
Critical care (London, England)
ISSN: 1466-609X
Titre abrégé: Crit Care
Pays: England
ID NLM: 9801902
Informations de publication
Date de publication:
30 Oct 2024
30 Oct 2024
Historique:
received:
17
08
2024
accepted:
19
10
2024
medline:
31
10
2024
pubmed:
31
10
2024
entrez:
31
10
2024
Statut:
epublish
Résumé
Coagulopathy is part of the pathological host response to infection in sepsis. Higher plasma concentrations of both tissue factor (TF) and tissue factor pathway inhibitor (TFPI) are associated with occurrence of disseminated intravascular coagulation (DIC), multi-organ dysfunction and increased mortality in patients with sepsis. Currently no treatment approaches specifically targeting this axis are available. We hypothesize that therapeutic plasma exchange (TPE) might limit this coagulopathy by restoring the balance of plasma proteins. This was a pooled post-hoc biobank analysis including 51 patients with early (shock onset < 24 h) and severe (norepinephrine dose > 0.4 μg/kg/min) septic shock, who were either receiving standard of care treatment (SOC, n = 14) or SOC + one single TPE (n = 37). Plasma concentrations of TF and TFPI were measured both at- and 6 h after study inclusion. The effect of TPE on concentrations of TF and TFPI was investigated and compared to SOC patients. Further, baseline TF and TFPI concentrations were used to modulate and predict clinical response to adjunctive TPE, indicated by longitudinal reduction of lactate concentrations over the first 24 h following study inclusion. TPE led to a significant reduction in circulating concentrations of both TF and TFPI while no difference was observed in the SOC group. Relative change of TF within 6 h was + 14 (-0.8 to + 30.4) % (p = 0.089) in the SOC and -18.3 (-32.6 to -2.2) % (p < 0.001) in the TPE group (between group p < 0.001). Similarly, relative change of TFPI was + 14.4 (-2.3 to + 30.9) % (p = 0.076) in the SOC and -20 (-32.8 to -7.9) % (p < 0.001) in the TPE group (between group p = 0.022). The ratio of TF to TFPI remained unchanged in both SOC and TPE groups. SOC patients exhibited an increase in lactate over the initial 24 h when TF and TFPI concentrations were higher at baseline. In contrast, patients undergoing TPE experienced a sustained longitudinal reduction of lactate concentrations across all levels of baseline TF and TFPI elevations. In a multivariate mixed-effects model, higher baseline TF (p = 0.003) and TFPI (p = 0.053) levels led to greater longitudinal lactate concentration reduction effects in the TPE group. Adjunctive TPE in septic shock is associated with a significant removal of both TF and TFPI, which may contribute to the early hemodynamic improvement observed in septic shock patients receiving TPE. Higher baseline TF (and TFPI) plasma concentrations were identified as a putative predictor of treatment response that could be useful for predictive enrichment strategies in future clinical trials.
Sections du résumé
BACKGROUND
BACKGROUND
Coagulopathy is part of the pathological host response to infection in sepsis. Higher plasma concentrations of both tissue factor (TF) and tissue factor pathway inhibitor (TFPI) are associated with occurrence of disseminated intravascular coagulation (DIC), multi-organ dysfunction and increased mortality in patients with sepsis. Currently no treatment approaches specifically targeting this axis are available. We hypothesize that therapeutic plasma exchange (TPE) might limit this coagulopathy by restoring the balance of plasma proteins.
METHODS
METHODS
This was a pooled post-hoc biobank analysis including 51 patients with early (shock onset < 24 h) and severe (norepinephrine dose > 0.4 μg/kg/min) septic shock, who were either receiving standard of care treatment (SOC, n = 14) or SOC + one single TPE (n = 37). Plasma concentrations of TF and TFPI were measured both at- and 6 h after study inclusion. The effect of TPE on concentrations of TF and TFPI was investigated and compared to SOC patients. Further, baseline TF and TFPI concentrations were used to modulate and predict clinical response to adjunctive TPE, indicated by longitudinal reduction of lactate concentrations over the first 24 h following study inclusion.
RESULTS
RESULTS
TPE led to a significant reduction in circulating concentrations of both TF and TFPI while no difference was observed in the SOC group. Relative change of TF within 6 h was + 14 (-0.8 to + 30.4) % (p = 0.089) in the SOC and -18.3 (-32.6 to -2.2) % (p < 0.001) in the TPE group (between group p < 0.001). Similarly, relative change of TFPI was + 14.4 (-2.3 to + 30.9) % (p = 0.076) in the SOC and -20 (-32.8 to -7.9) % (p < 0.001) in the TPE group (between group p = 0.022). The ratio of TF to TFPI remained unchanged in both SOC and TPE groups. SOC patients exhibited an increase in lactate over the initial 24 h when TF and TFPI concentrations were higher at baseline. In contrast, patients undergoing TPE experienced a sustained longitudinal reduction of lactate concentrations across all levels of baseline TF and TFPI elevations. In a multivariate mixed-effects model, higher baseline TF (p = 0.003) and TFPI (p = 0.053) levels led to greater longitudinal lactate concentration reduction effects in the TPE group.
CONCLUSIONS
CONCLUSIONS
Adjunctive TPE in septic shock is associated with a significant removal of both TF and TFPI, which may contribute to the early hemodynamic improvement observed in septic shock patients receiving TPE. Higher baseline TF (and TFPI) plasma concentrations were identified as a putative predictor of treatment response that could be useful for predictive enrichment strategies in future clinical trials.
Identifiants
pubmed: 39478586
doi: 10.1186/s13054-024-05142-4
pii: 10.1186/s13054-024-05142-4
doi:
Substances chimiques
Lipoproteins
0
lipoprotein-associated coagulation inhibitor
0
Thromboplastin
9035-58-9
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
351Informations de copyright
© 2024. The Author(s).
Références
Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016;315(8):801–10.
doi: 10.1001/jama.2016.0287
pubmed: 26903338
Steinhagen F, Schmidt SV, Schewe JC, Peukert K, Klinman DM, Bode C. Immunotherapy in sepsis - brake or accelerate? Pharmacol Ther. 2020;208: 107476.
doi: 10.1016/j.pharmthera.2020.107476
pubmed: 31931100
Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021;47(11):1181–247.
doi: 10.1007/s00134-021-06506-y
pubmed: 34599691
pmcid: 8486643
Engel C, Brunkhorst FM, Bone HG, Brunkhorst R, Gerlach H, Grond S, et al. Epidemiology of sepsis in Germany: results from a national prospective multicenter study. Intensive Care Med. 2007;33(4):606–18.
doi: 10.1007/s00134-006-0517-7
pubmed: 17323051
Bode C, Weis S, Sauer A, Wendel-Garcia P, David S. Targeting the host response in sepsis: current approaches and future evidence. Crit Care. 2023;27(1):478.
doi: 10.1186/s13054-023-04762-6
pubmed: 38057824
pmcid: 10698949
Abraham E, Reinhart K, Svoboda P, Seibert A, Olthoff D, Dal Nogare A, et al. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med. 2001;29(11):2081–9.
doi: 10.1097/00003246-200111000-00007
pubmed: 11700399
Semeraro N, Ammollo CT, Semeraro F, Colucci M. Coagulopathy of Acute Sepsis. Semin Thromb Hemost. 2015;41(6):650–8.
doi: 10.1055/s-0035-1556730
pubmed: 26305237
Gando S, Nanzaki S, Sasaki S, Aoi K, Kemmotsu O. Activation of the extrinsic coagulation pathway in patients with severe sepsis and septic shock. Crit Care Med. 1998;26(12):2005–9.
doi: 10.1097/00003246-199812000-00030
pubmed: 9875912
Musgrave KM, Scott J, Sendama W, Gardner AI, Dewar F, Lake CJ, et al. Tissue factor expression in monocyte subsets during human immunothrombosis, endotoxemia and sepsis. Thromb Res. 2023;228:10–20.
doi: 10.1016/j.thromres.2023.05.018
pubmed: 37263122
Creasey AA, Chang AC, Feigen L, Wun TC, Taylor FB Jr, Hinshaw LB. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest. 1993;91(6):2850–60.
doi: 10.1172/JCI116529
pubmed: 8514893
pmcid: 443354
Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003;290(2):238–47.
doi: 10.1001/jama.290.2.238
pubmed: 12851279
Lehner GF, Tobiasch AK, Perschinka F, Mayerhofer T, Waditzer M, Haller V, et al. Associations of tissue factor and tissue factor pathway inhibitor with organ dysfunctions in septic shock. Sci Rep. 2024;14(1):14468.
doi: 10.1038/s41598-024-65262-3
pubmed: 38914630
pmcid: 11196691
Knaup H, Stahl K, Schmidt BMW, Idowu TO, Busch M, Wiesner O, et al. Early therapeutic plasma exchange in septic shock: a prospective open-label nonrandomized pilot study focusing on safety, hemodynamics, vascular barrier function, and biologic markers. Crit Care. 2018;22(1):285.
doi: 10.1186/s13054-018-2220-9
pubmed: 30373638
pmcid: 6206942
David S, Bode C, Putensen C, Welte T, Stahl K. Adjuvant therapeutic plasma exchange in septic shock. Intensive Care Med. 2021;47(3):352–4.
doi: 10.1007/s00134-020-06339-1
pubmed: 33471132
pmcid: 7816555
Stahl K, Wand P, Seeliger B, Wendel-Garcia PD, Schmidt JJ, Schmidt BMW, et al. Clinical and biochemical endpoints and predictors of response to plasma exchange in septic shock: results from a randomized controlled trial. Crit Care. 2022;26(1):134.
doi: 10.1186/s13054-022-04003-2
pubmed: 35551628
pmcid: 9097091
Stahl K, Schmidt JJ, Seeliger B, Schmidt BMW, Welte T, Haller H, et al. Effect of therapeutic plasma exchange on endothelial activation and coagulation-related parameters in septic shock. Crit Care. 2020;24(1):71.
doi: 10.1186/s13054-020-2799-5
pubmed: 32122366
pmcid: 7053051
Stahl K, Hillebrand UC, Kiyan Y, Seeliger B, Schmidt JJ, Schenk H, et al. Effects of therapeutic plasma exchange on the endothelial glycocalyx in septic shock. Intensive Care Med Exp. 2021;9(1):57.
doi: 10.1186/s40635-021-00417-4
pubmed: 34817751
pmcid: 8611389
Stahl K, Bikker R, Seeliger B, Schmidt JJ, Schenk H, Schmidt BMW, et al. Effect of therapeutic plasma exchange on immunoglobulin deficiency in early and severe septic shock. J Intensive Care Med. 2021;36(12):1491–7.
doi: 10.1177/0885066620965169
pubmed: 33063613
David S, Stahl K. To remove and replace—a role for plasma exchange in counterbalancing the host response in sepsis. Crit Care. 2019;23(1):14.
doi: 10.1186/s13054-018-2289-1
pubmed: 30654829
pmcid: 6337776
Lee OPE, Kanesan N, Leow EH, Sultana R, Chor YK, Gan CS, et al. Survival benefits of therapeutic plasma exchange in severe sepsis and septic shock: a systematic review and meta-analysis. J Intensive Care Med. 2023;38(7):598–611.
doi: 10.1177/08850666231170775
pubmed: 37097910
Kuklin V, Sovershaev M, Bjerner J, Keith P, Scott LK, Thomas OMT, et al. Influence of therapeutic plasma exchange treatment on short-term mortality of critically ill adult patients with sepsis-induced organ dysfunction: a systematic review and meta-analysis. Crit Care. 2024;28(1):12.
doi: 10.1186/s13054-023-04795-x
pubmed: 38178170
pmcid: 10768220
Rimmer E, Houston BL, Kumar A, Abou-Setta AM, Friesen C, Marshall JC, et al. The efficacy and safety of plasma exchange in patients with sepsis and septic shock: a systematic review and meta-analysis. Crit Care. 2014;18(6):699.
doi: 10.1186/s13054-014-0699-2
pubmed: 25527094
pmcid: 4318234
Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43(3):304–77.
doi: 10.1007/s00134-017-4683-6
pubmed: 28101605
David S, Hoeper MM, Kielstein JT. Plasma exchange in treatment refractory septic shock : presentation of a therapeutic add-on strategy. Med Klin, Intensivmed und Notfallmedizin. 2017;112(1):42–6.
doi: 10.1007/s00063-015-0117-9
Gando S, Kameue T, Morimoto Y, Matsuda N, Hayakawa M, Kemmotsu O. Tissue factor production not balanced by tissue factor pathway inhibitor in sepsis promotes poor prognosis. Crit Care Med. 2002;30(8):1729–34.
doi: 10.1097/00003246-200208000-00009
pubmed: 12163784
Amaral A, Opal SM, Vincent JL. Coagulation in sepsis. Intensive Care Med. 2004;30(6):1032–40.
doi: 10.1007/s00134-004-2291-8
pubmed: 15148567
Maneta E, Aivalioti E, Tual-Chalot S, Emini Veseli B, Gatsiou A, Stamatelopoulos K, et al. Endothelial dysfunction and immunothrombosis in sepsis. Front Immunol. 2023;14:1144229.
doi: 10.3389/fimmu.2023.1144229
pubmed: 37081895
pmcid: 10110956
Williams B, Zou L, Pittet JF, Chao W. Sepsis-induced coagulopathy: a comprehensive narrative review of pathophysiology, clinical presentation, diagnosis, and management strategies. Anesth Analg. 2024;138(4):696–711.
pubmed: 38324297
pmcid: 10916756
Popescu NI, Lupu C, Lupu F. Disseminated intravascular coagulation and its immune mechanisms. Blood. 2022;139(13):1973–86.
doi: 10.1182/blood.2020007208
pubmed: 34428280
pmcid: 8972096
Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med. 2012;366(22):2055–64.
doi: 10.1056/NEJMoa1202290
pubmed: 22616830
Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, et al. Caring for the critically ill patient High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA. 2001;286(15):1869–78.
doi: 10.1001/jama.286.15.1869
pubmed: 11597289
Vincent JL, Francois B, Zabolotskikh I, Daga MK, Lascarrou JB, Kirov MY, et al. Effect of a recombinant human soluble thrombomodulin on mortality in patients with sepsis-associated coagulopathy: the scarlet randomized clinical trial. JAMA. 2019;321(20):1993–2002.
doi: 10.1001/jama.2019.5358
pubmed: 31104069
pmcid: 6547077
David S, Bode C, Stahl K. EXCHANGE-2: investigating the efficacy of add-on plasma exchange as an adjunctive strategy against septic shock-a study protocol for a randomized, prospective, multicenter, open-label, controlled, parallel-group trial. Trials. 2023;24(1):277.
doi: 10.1186/s13063-023-07300-5
pubmed: 37061693
pmcid: 10105400